RaySearch have announces the acquisition of DrugLog from Pharmacolog for the purchase price of SEK 7 million.

DrugLog is a solution for verifying the identity and concentration of compounded injectable medications, used for cancer treatment with cytostatic drugs (chemotherapy). Through this agreement, RaySearch acquires full ownership of all rights to the product for its application in the field of oncology, including the measuring device, calibration parameters, source code, as well as intellectual property rights. The purchase price for the asset acquisition amounts to SEK 7 million.

Since its inception, RaySearch has focused on software for optimizing and planning radiation therapy. However, the long-term vision is to provide software support for all types of cancer treatments, including chemotherapy and surgery.”

“Since its inception, RaySearch has focused on software for optimizing and planning radiation therapy. However, the long-term vision is to provide software support for all types of cancer treatments, including chemotherapy and surgery. As a first step, we intend to add support for treatment planning in RayStation and workflows in RayCare for chemotherapy management. We anticipate that these extensions will be launched by 2026 at the latest. DrugLog will be an excellent complement to this and significantly improve and simplify quality assurance in cancer treatment with chemotherapy,” says Johan Löf, founder and CEO, RaySearch:.

Photo of Johan Löf: RaySearch